Business Wire

Neeva Brings Responsible, Citation-Backed AI Powered Search to Europe

13.2.2023 14:00:00 EET | Business Wire | Press release

Share

Advert and tracker-free search engine Neeva has today launched NeevaAI in Europe, which harnesses the power of artificial intelligence (AI) to deliver an experience that combines the best of large language models such as ChatGPT with the authority and timeliness of search.

Following a successful beta launch in the US in December 2022, NeevaAI is available to Free Basic and Premium users across the world from today. NeevaAI will be launching its English Language version in the UK and Canada, as well as local language versions in Germany, France and Spain.

NeevaAI provides a synthesised single answer with linked sources pulled together from the most relevant sites for a query, allowing users to determine the authenticity and reliability of the cited sources. The feature offers current information by crawling hundreds of millions of pages a day and serving from its independent index of billions of pages. By combining AI with Neeva's in-house search stack that eschews ads and advertisers, results are fast, timely, bias-free and relevant.

Real-time summaries backed by sources

Unlike other AI search offerings, NeevaAI offers current information to the user by interrogating a page, understanding its contents and incoming links to determine whether the page is useful and authoritative and cite the information source. NeevaAI does this in real time as the web changes, which is vital in our fast paced world.

In a feature unique to Neeva, NeevaAI also provides citation cards, in which a search query returns a visual search result with machine learning summaries from all the top results and swipeable cards highlighting authoritative information about the researched topic. The cards also suggest important research questions for the searcher.

Neeva Founder and CEO, Sridhar Ramaswamy comments: “AI is already beginning to make search one of the first and most clearly disrupted industries. NeevaAI leverages in-house LLMs and refined training models with its full system search stack to bring authentic real time AI search to the everyones. Our goal has been to responsibly integrate AI and provide authoritative answers that you can trust.”

Support for publishers in a post-ChatGPT world

Publishers and content creators stand to be greatly impacted by certain AI search models. AI will fundamentally shift individuals’ relationship to finding and consuming information. For publishers, this should be canary in the coal mine, and failing to adapt to this new reality could prove catastrophic for their businesses.

Nowhere is the threat more immediate than in search. As search engines become answer engines, publisher content will get sucked into the AI bots and served back to users without attribution or links. Without links embedded in the AI answer, users won’t find their way to a publisher’s website, effectively choking off the referral traffic pipeline. Significant drops in referral traffic will lead to material impacts on ad revenue especially at a time when most publishers are fighting just to stay afloat. To make matters worse, that same content will also be used to further train large language models (LLMs) exacerbating the publisher’s dilemma.

Neeva is committed to helping publishers leverage AI and LLMs to re-take ownership of the relationships with their users. Neeva is working to help publishers integrate fluent AI search natively in their websites allowing users to discover and consume content seamlessly. Moreover, to support publishers, whose referral traffic is now at greater risk from AI answer bots, Neeva has committed 20% of its topline revenue to content creator and publisher partners when their content is used to directly answer a Neeva customer’s query.

Since launching in the US in 2021, and Europe in late 2022, Neeva has amassed nearly 2 million users. It has built one of the largest independent search stacks crawling hundreds of millions of pages a day and an index of billions. By combining AI with Neeva’s in-house search stack, NeevaAI’s results are lightning fast, timely, and relevant.

ENDS

About Neeva

Neeva is the world’s first ads-free, private subscription search engine powered by AI. Neeva focuses entirely on the consumer, delivering only real, high quality, trustworthy results. Neeva is leading a new AI frontier by leveraging in-house LLMs and refined training models with our full system search stack to bring authentic real-time AI search to everyone. Neeva blocks third-party website trackers, and will never sell or share customer data with anyone, especially advertisers. Neeva also makes it easy to search within personal email accounts, calendars, and cloud storage platforms surfacing the most important information from the same familiar search box. The company was founded by former executives from Google and YouTube. Learn more and start searching today at neeva.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Contact details
press@neeva.co

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye